Karyopharm Therapeutics Inc.
KPTI
$5.46
$0.101.87%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 16.12% | 26.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.12% | 26.37% | |||
| Cost of Revenue | -3.49% | -5.79% | |||
| Gross Profit | 178.41% | 169.28% | |||
| SG&A Expenses | -6.57% | 4.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.90% | -1.51% | |||
| Operating Income | 37.59% | 26.67% | |||
| Income Before Tax | 11.07% | -58.85% | |||
| Income Tax Expenses | -15.00% | 11.11% | |||
| Earnings from Continuing Operations | 11.07% | -58.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.07% | -58.78% | |||
| EBIT | 37.59% | 26.67% | |||
| EBITDA | 37.89% | 26.73% | |||
| EPS Basic | 11.58% | -56.01% | |||
| Normalized Basic EPS | 11.57% | -56.09% | |||
| EPS Diluted | 11.58% | -56.01% | |||
| Normalized Diluted EPS | 11.57% | -56.09% | |||
| Average Basic Shares Outstanding | 0.57% | 1.77% | |||
| Average Diluted Shares Outstanding | 0.57% | 1.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||